FNArena Windows

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

ASX CODE LAST PRICE % MOVE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET UPSIDE/DOWNSIDE
4DX $1.58

2.60%

$2.55 $0.23

$2.075

31.3%

AT1 $0.03 0.00% $0.03 $0.01

AYA $3.03

1.00%

$4.02 $0.42

BB1 $0.81

1.25%

$0.83 $0.24

BRN $0.17 0.00% $0.45 $0.17

CAT $5.04

7.92%

$7.72 $2.98 -41.1

$6.567

30.3%

CBL $0.07

-5.71%

$0.09 $0.03

CGS $2.60

0.39%

$2.97 $0.95

CMP $0.33

0.61%

$0.42 $0.24

COH $275.98

0.99%

$323.00 $246.14 39.7

$306.74

11.1%

CSX $0.65

-3.01%

$0.88 $0.31

CU6 $3.51

-3.57%

$6.44 $1.43

$6.40

82.3%

CVB $0.07 0.00% $0.18 $0.06

$0.15

102.7%

CYC $0.68

-2.86%

$2.47 $0.56

$1.50

120.6%

EBR $1.04

-0.95%

$2.08 $0.86

$2.645

154.3%

EMV $1.82

3.71%

$2.43 $1.63

$3.15

73.6%

EYE $0.13

-3.85%

$0.20 $0.09

FPH $31.83

-1.52%

$35.75 $29.08 49.0

IME $0.32

3.23%

$0.45 $0.22

$0.35

9.4%

IMR $1.39

4.12%

$1.86 $0.89

$2.22

59.7%

IPD $0.04

2.86%

$0.06 $0.03

$0.125

247.2%

LDX $0.22

4.76%

$0.28 $0.02

MX1 $0.08

-3.49%

$0.12 $0.04

$0.17

104.8%

NAN $4.14

1.47%

$5.18 $2.88 61.0

$4.55

9.9%

ONE $0.31

1.67%

$0.38 $0.17

$0.25

-18.0%

PCK $0.04

5.41%

$0.11 $0.02

PEB $0.15 0.00% $0.19 $0.05

PGC $0.30

1.69%

$0.59 $0.24 14.3

$0.495

65.0%

PME $260.09

0.03%

$336.00 $161.64 174.0

$322.767

24.1%

RMD $38.52

-0.34%

$45.25 $32.04 22.2

$49.01

27.2%

SOM $0.79

1.94%

$0.95 $0.34 49.4

$0.99

25.3%

TRJ $0.67

3.08%

$1.14 $0.63 22.0

$1.25

86.6%

Previous Stories
Margins Signal Integral Diagnostics Recovery

Sep 07 2023

Analysts identify a second half FY23 inflection point for Integral Diagnostics


ResMed: Finding A Base?

Aug 15 2023

After a sharp pullback for ResMed, Michael Gable of Fairmont Equities suggests a base may soon be formed, providing a buying opportunity


August Turns ResMed Into Nigel NoMates

Aug 09 2023

A miss on the Q4 gross margin and Eli Lilly targeting the CPAP market have kept ResMed shares under selling pressure since Friday last week


Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023

Tim Boreham takes a look at Lumos Diagnostics, which specialises in rapid point-of-care tests to help healthcare professionals diagnose and manage medical conditions more accurately


Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023

Following FY23 results for Fisher & Paykel, brokers lowered earnings forecasts on a delayed margin recovery and future spending plans


Dr Boreham’s Crucible: Impedimed

May 08 2023

Tim Boreham reports a change in CEO has given cancer monitoring biotech Impedimed a new lease of life


Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea is ResMed


Dr Boreham’s Crucible: Volpara Health Technologies

Apr 26 2023

Volpara Health Technologies is revolutionising breast cancer detection. Tim Boreham investigates


Dr Boreham’s Crucible: SDI

Mar 16 2023

Tim Boreham gets his teeth into the opportunity ahead for listed dental products company SDI


Dr Boreham’s Crucible: Cochlear

Mar 03 2023

Short term hiccups aside, Cochlear continues to play the long game, reports Tim Boreham